GSK plc (GSK) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong growth in key areas such as Specialty Medicines, HIV, and oncology, along with upgraded revenue and EPS guidance. The Q&A session reveals strategic initiatives, especially in COPD and HIV, and addresses R&D realignment. Despite some concerns over regulatory strategies, the overall sentiment is positive, with strong financial performance and optimistic guidance suggesting a stock price increase.
Key Financial Performance
Sales Sales were up 7% to more than GBP 32 billion. Growth was driven by Specialty Medicines, which were up 17%, with vaccines also contributing.
Core Operating Profit Core operating profit grew 11%. This was supported by a 3% increase in SG&A as investment in product launches was balanced with productivity improvements.
Earnings Per Share (EPS) EPS was up 12%. This was supported by the share buyback and lower interest expense due to strong operating cash flows.
Cash Generation Cash generation was strong at GBP 8.9 billion, supporting future investment and returns to shareholders.
Specialty Medicines Specialty Medicines sales were up 17%, driven by strong growth in areas like oncology and respiratory.
Vaccines Vaccines sales were GBP 9.2 billion, up 2%, driven by European and international region sales of Shingrix and Bexero.
Benlysta Benlysta grew 22%, driven by higher demand and supported by all major guidelines.
Nucala Nucala grew 15% and delivered $2 billion for the year. This is the 10th consecutive year of double-digit growth for Nucala.
Jemperli Jemperli sales were up 89%, reflecting its differentiated profile in endometrial cancer.
Ojjaara Ojjaara grew 60%, driven by growth in all markets following the new data at EHA, emphasizing the importance of early intervention.
ZEJULA ZEJULA sales decreased, reflecting FDA labeling restrictions.
HIV Sales Sales growth was 11% in the year, powered by accelerated patient demand for long-acting injectables and foundational oral 2-drug regimen, Dovato.
Cabenuva Cabenuva grew 42% in 2025, fueled by patient demand and accelerated switches from competitor products.
Aplitude Aplitude grew 62% in 2025, withstanding any impact from a competitor launch.
Shingrix Shingrix sales were GBP 3.6 billion, up 8%, driven by Europe and international region, offset by the U.S.
Bexero Bexero sales were up 16% for the year, driven by demand in Europe and international regions.
Arexvy Arexvy sales were up 2% for the year, driven by ex-U.S. growth.
TRELEGY TRELEGY continues to be the top-selling brand for asthma and COPD globally.
Free Cash Flow Free cash flow increased to GBP 4 billion or more than GBP 5 billion, excluding Zantac, driven by strong CFO.
Net Debt to EBITDA Net debt to EBITDA was relatively stable year-on-year at 1.3x, including the absorption of Zantac and the buyback.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Blenrep and Exdensur: Maximizing launch products like Blenrep and Exdensur to drive top-line growth.
Late-stage portfolio: Accelerating key assets like B7-H3, B7-H4, Velzatinib in oncology, and Effi in MASH.
Food allergy IgE antibody: Acquisition of Ozekibart to expand into food allergy treatment.
Exdensur: Approved in the U.S., U.K., and Japan, showing significant reduction in exacerbations for asthma patients.
BLENREP: Approved in 15 markets globally for multiple myeloma.
HIV market: Cabenuva grew 42% in 2025, capturing 75% of U.S. market switches from competitors.
Vaccines: Shingrix sales grew 8% in Europe and international regions, offset by U.S. slowdown.
Meningitis: Bexero sales up 16%, driven by outbreaks and geographic expansion.
Operational efficiencies: SG&A margin improved by 90 bps, and gross margin grew by 40 bps due to portfolio transition.
Cash generation: GBP 8.9 billion generated, supporting investments and shareholder returns.
Productivity initiatives: GBP 300 million charges in Q4 to drive productivity benefits.
Pipeline acceleration: 10 pivotal trial starts planned for 2026, including ADCs and HIV treatments.
Business development: Acquisition of Rapp Therapeutics to access innovation in food allergy treatment.
Leadership changes: New Head of Global Product Strategy and Head of R&D to enhance focus on execution and innovation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
ZEJULA sales decrease: Reflecting FDA labeling restrictions, which could impact revenue and market share.
BLENREP adoption challenges: Slow ramp-up due to the need to support prescribers and patients for a positive first experience, indicating potential delays in revenue realization.
Shingrix sales in the U.S.: Offset by slowing U.S. immunization rates and inventory management issues in China, which could impact overall vaccine sales.
GenMed sales decline: Pricing pressures and generic competition in the established portfolio, leading to low single-digit decline to stable growth.
Medicare redesign impact: The Inflation Reduction Act caused a financial impact near the upper end of the $400 million to $500 million range, affecting U.S. operations.
Currency headwinds: Potential negative impact of minus 3% on sales and minus 6% on operating profit if current exchange rates persist.
Pipeline acceleration risks: Increased R&D expenditure to accelerate pipeline development, which may not yield expected returns if projects fail or are delayed.
Dolutegravir loss of exclusivity: Upcoming loss of exclusivity poses a significant risk to revenue, requiring strategic adjustments to offset the impact.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Sales Growth: Sales growth is expected to be 3% to 5%, with specialty medicines leading at low double-digit growth, HIV at mid- to high single-digit growth, and vaccines and GenMed expected to be stable or decline slightly.
Core Operating Profit and EPS: Core operating profit and core EPS are projected to grow at 7% to 9%.
Dividend: A dividend of 70p is planned, representing a 6% increase.
Specialty Medicines: Specialty medicines are expected to grow at a low double-digit percentage, driven by launches like Exdensur and BLENREP, and advancements in oncology and respiratory portfolios.
HIV Portfolio: HIV sales are projected to grow mid- to high single digits, with a focus on long-acting regimens and new pipeline assets like VH184 and VH499.
Vaccines: Vaccines sales are expected to be stable or decline slightly, with Shingrix growth outside the U.S. offset by slowing U.S. immunization rates.
R&D Investments: R&D spending will grow ahead of sales to support pipeline advancements, including pivotal trials for ADCs, HIV treatments, and respiratory assets.
Pipeline Developments: Key pipeline advancements include pivotal trials for Efimosfermin in NASH, Velzatinib in oncology, and long-acting HIV treatments. The company plans 10 pivotal trial starts in 2026.
Operational Efficiency: SG&A expenses will grow at a low single-digit rate, benefiting from productivity initiatives.
Currency Impact: Currency is expected to be a headwind, potentially reducing sales by 3% and operating profit by 6% if current rates persist.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend upgrade: The dividend was upgraded by 2p to 66p, declared for the year 2025.
Future dividend guidance: For 2026, the company expects to pay a dividend of 70p, a 6% increase from 2025.
Share buyback program: In 2025, the company repurchased 93 million shares at an average price of 1473, with the remaining GBP 0.6 billion to be completed in the first half of 2026.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on R&D and commercial strategy in COPD and asthma, considering overlapping products like Nucala, Exdensur, IL-33, and TSP?
A:The company is focusing on a range of long-acting mechanisms to address the heterogeneous nature of COPD. Nucala and Exdensur target the high eosinophil population, while IL-33 is positioned for the low T2 population. Pivotal studies for long-acting TSLPs and IL-33 are expected to start in 2-3 years. The launch of Nucala COPD in the U.S. is progressing well, capturing 43-46% of new patient starts.
Q:When could we see the 6-monthly treatment and PrEP Phase III trial start for HIV, and what are the commercial implications of 4-month and 6-month treatments?
A:The Q6M treatment regimen selection is on track for mid-year, with Phase II studies starting this year and a launch expected in 2028-2030. The Q6M treatment could address 50% of patients, significantly expanding the market. Q4M treatment is also expected to see rapid adoption, doubling clinic capacity and transitioning patients from Q2M to Q4M and eventually to Q6M.
Q:Does the $40 billion revenue target include recent acquisitions?
A:The $40 billion target includes some recent deals like IDRx and Efimosfermin but excludes others like Rapp, which was recently announced.
Q:What is the update on the launch trajectory for Blenrep?
A:The launch of Blenrep is progressing systematically but slowly due to the need for coordination with eye care professionals. In the U.K., 70% of patients are covered in open accounts, and the U.S. is expected to follow a similar trajectory. The focus is on ensuring positive initial experiences rather than rapid ramp-up.
Q:Is there a reduction in R&D staff, and what is the context?
A:The reduction in R&D staff is part of a broader strategy to dynamically shift resources to more promising programs and ensure efficient use of capital.
Q:What is the launch strategy for Exdensur in severe asthma?
A:The focus is on bio-naive patients rather than active switching from other biologics. The 6-monthly dosing of Exdensur is expected to attract patients who would otherwise not start on biologics, leveraging its unique positioning as the first ultra-long-acting biologic.
Q:How many physicians have been through the REMS certification process for Blenrep?
A:Hundreds of physicians have been through the REMS certification process, and this number is expected to grow.
Q:What is the purpose of the pooled analysis for Camlipixant, and has the FDA confirmed its acceptance?
A:The pooled analysis provides an option for regulatory filing, but the company remains confident in the outcomes of both KALM-1 and KALM-2 trials.
Q:What were the sales to GEFA for Shingrix in Q4, and what is the confidence level for 2026?
A:Sales to GEFA in Q4 were $100 million. The company is confident in the growth trajectory, with underlying demand in China improving and market share increasing to 93%.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer on the regulatory strategy for Camlipixant, specifically whether the FDA would accept a filing based on pooled data if one trial is negative. Additionally, there was no detailed explanation of the broader cost savings program under the simplification strategy.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASO
BLENREP
Efimosfermin
Exdensur
Eye Care
GBP
Head
III trial
KPIs
MASH
MRD
MenB
NASH
Nina slide
Phase II
Phase III
Product
Ris Rez
SCLC
TRELEGY
Velzatinib
antibody
approval trial
asset potential
currency headwind
digit decline
enzyme
food allergy
hepatitis
landscape
liver
patient anemia
patient stage
portfolio transition
position
recruitment
regimen selection
sale immunization
GSK Transcript
GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
GSK plc (GSK) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call summary and Q&A indicate positive sentiment. Specialty medicines and HIV portfolios show promising growth, supported by strong pipeline developments. The 6% dividend increase and strategic focus on operational efficiency bolster confidence. Despite some uncertainties, optimistic guidance and new product launches, such as Exdensur, provide a positive outlook. The market reaction is expected to be positive, with a 2% to 8% increase in stock price over the next two weeks.
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
GSK plc (GSK) Q4 2025 Earnings Call Transcript
Positive2-4
The earnings call summary highlights strong growth in key areas such as Specialty Medicines, HIV, and oncology, along with upgraded revenue and EPS guidance. The Q&A session reveals strategic initiatives, especially in COPD and HIV, and addresses R&D realignment. Despite some concerns over regulatory strategies, the overall sentiment is positive, with strong financial performance and optimistic guidance suggesting a stock price increase.
GSK Slides
GSK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
